IMPORTANT USER INFORMATION

Amneal Pharmaceuticals LLC and Steriscience Pte Limited

Subject: **IMPORTANT DRUG INFORMATION** – Proper IV Line Flushing Following Administration of FOCINVEZ™ (fosaprepitant injection)

IMPORTANT DRUG INFORMATION

FOCINVEZ™ (fosaprepitant injection)

NDC 70121-2631-1

FOCINVEZ™ (fosaprepitant injection)

Dear Healthcare Practitioner:

Steriscience Pte Limited in conjunction with Amneal Pharmaceuticals LLC, is emphasizing the critical importance of adequately flushing the intravenous line after administering FOCINVEZ™ (fosaprepitant injection), NDC 70121-2631-1, to ensure proper drug delivery and reduce the risk of infusion-related complications.

Administration of subsequent drugs after administration of FOCINVEZ™ without adequate flushing may result in precipitation within the IV tubing, which may interfere with complete drug delivery and could increase the risk of infusion-related complications.

Administration Recommendations

1. Infuse FOCINVEZ™ according to the instructions provided in the package information leaflet 30 minutes prior to a chemotherapy drug.

2. Allow FOCINVEZ™ to come to room temperature before use if the injection is NOT stored at room temperature.

3. Use a vented infusion set when FOCINVEZ™ is infused from the bottle.

4. **Option 1.** Following administration of FOCINVEZ™, flush the IV set with a sufficient volume of 0.9% sodium chloride to ensure the full length of the tubing and catheter lumen is completely cleared of residual medication.



Administration Recommendations *(continued)*

Option 2. Replacement of a new IV set may be performed and can be used without flushing. However, flushing of the catheter lumen with 0.9% sodium chloride remains necessary to ensure complete drug clearance.

5. Proceed with the administration of other medications only after the flushing step has been completed.

Caution: Per the Package Instruction Leaflet do not mix FOCINVEZ™ with solutions for which physical and chemical compatibility have not been established. FOCINVEZ™ is incompatible with any solutions containing divalent cations (e.g., Ca, Mg), including Lactated Ringer's Solution and Hartmann's Solution.

REPORTING ADVERSE EVENTS AND MEDICAL INQUIRIES

Healthcare Practitioners are encouraged to report all adverse events experienced during the application or use of FOCINVEZ™ to Amneal Pharmaceuticals LLC at:

- **Phone:** 1-877-835-5472
- **Email:** Drugsafety@Amneal.com
- **Mail:** 50 Horseblock Road, Brookhaven, NY 11719

Please note that adverse reactions or quality related complaints experienced with the use of FOCINVEZ™ (fosaprepitant injection) may be reported to the FDA's MedWatch Adverse Event Reporting Program either online, by regular mail, or by fax:

- Complete and submit the report Online: www.fda.gov/medwatch/report.htm
- Regular mail or fax: download form at https://www.accessdata.fda.gov/scripts/medwatch/index.cfm or

Call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form or submit it by fax to 1-800-FDA-0178 (1-800-332-0178).

INDICATIONS

FOCINVEZ™ is a substance P/neurokinin-1 (NK1) receptor antagonist indicated in adults and pediatric patients 6 months of age and older, in combination with other antiemetic agents, for the prevention of:

- acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin.
- delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC).

Limitations of Use:

FOCINVEZ™ has not been studied for the treatment of established nausea and vomiting.

IMPORTANT SAFETY INFORMATION

Contraindications

- FOCINVEZ™ is contraindicated in patients who are hypersensitive to any component of the product.
- Concurrent use of FOCINVEZ™ with pimozide is contraindicated.

Warnings and Precautions

- **Clinically Significant CYP3A4 Interactions:** Fosaprepitant, a prodrug of aprepitant, is a weak inhibitor of CYP3A4, and aprepitant is a substrate, inhibitor, and inducer of CYP3A4. See full Prescribing Information for recommendations regarding contraindications, risk of adverse reactions, and dosage adjustment of FOCINVEZ™ and concomitant drugs.
- **Hypersensitivity Reactions:** Serious hypersensitivity reactions, including anaphylaxis and anaphylactic shock, during or soon after infusion of fosaprepitant have occurred. Monitor patients during and after infusion. If hypersensitivity reactions occur, discontinue the infusion and administer appropriate medical therapy. Do not reinitiate FOCINVEZ™ in patients who experienced these symptoms with previous use.
- **Infusion Site Reactions:** Infusion site reactions (ISRs), including thrombophlebitis and vasculitis, have been reported with the use of intravenous fosaprepitant. The majority of severe ISRs were reported with concomitant vesicant (anthracycline-based) chemotherapy administration. Avoid infusion into small veins. Discontinue infusion and administer treatment if a severe reaction develops.
- **Warfarin:** Coadministration of fosaprepitant with warfarin, a CYP2C9 substrate, may result in a clinically significant decrease in the international normalized ratio (INR) of prothrombin time. Monitor the INR in patients on chronic warfarin therapy in the 2-week period, particularly at 7 to 10 days, following initiation of FOCINVEZ™ with each chemotherapy cycle.
- **Hormonal Contraceptives:** The efficacy of hormonal contraceptives may be reduced during treatment with FOCINVEZ™ and for 1 month following administration of the last dose of either fosaprepitant or oral aprepitant. Advise patients to use effective alternative or back-up methods of contraception.

Adverse Drug Reactions

- The most common adverse drug reactions in adults (≥2%) treated with FOCINVEZ™ are neutropenia, leukopenia, peripheral neuropathy, anemia, fatigue, diarrhea, asthenia, dyspepsia, urinary tract infection, pain in extremity.
- Adverse reactions in pediatric patients treated with FOCINVEZ™ are similar to adults.

Drug Interactions

- Co-administration of FOCINVEZ™ with drugs that are inhibitors or inducers of CYP3A4 may result in increased or decreased plasma concentrations of aprepitant.
- See full Prescribing Information for a list of clinically significant drug interactions.

Use in Specific Populations

- Pregnancy: There are insufficient data on the use of fosaprepitant in pregnant women to identify a drug-associated risk of major birth defects, miscarriage or other adverse maternal or fetal outcomes.
- Lactation: There are no data on the presence of aprepitant in human milk.

To report SUSPECTED ADVERSE REACTIONS, contact Amneal Biosciences, a division of Amneal Pharmaceuticals LLC at 1-877-835-5472 or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see accompanying full Prescribing Information.

Amneal